What we are watching
Top 10 by severity and recency
Reimbursement watchlist
GLP-1, SGLT2, and CGM coverage decisions are reshaping the diabetes economics base.
Coverage and formulary decisions on GLP-1 receptor agonists for type 2 diabetes and obesity, SGLT2 inhibitors with cardiorenal indications, and continuous glucose monitors for type 1 and intensively managed type 2 populations are in active rewrite across CMS and the major commercial PBMs. AimwellBio's CMS LCD ingest is in calibration; full coverage activates on the next refresh cycle. Manufacturer commentary, MAC bulletins, and proposed-policy comment periods will populate this surface as the indexer comes online.
Saudi Arabia · Vision 2030
Saudi Arabia carries one of the highest diabetes prevalence rates among adults globally. The Ministry of Health has positioned amputation reduction as a Vision 2030 priority.
The GCC + MENA cluster represents the highest-density sovereign-procurement opportunity for AimwellBio's diabetes intelligence layer. SFDA approvals, MOH formulary movements, and cross-border clinical infrastructure across Riyadh, Jeddah, Dubai, Abu Dhabi, Amman, and Cairo are already trackable through the indication-aware pipeline.
Decisions of this scale — coverage policy, capital procurement of GLP-1 supply, CGM rollout to primary care, and diabetic-foot prevention programs — cannot rest on a single source or vendor pipeline page. They require an adversarial verification layer with origin URLs, fetch timestamps, and reproducible claims for every signal.
Monitored issuers and operators
Volume & cadence of public disclosure
Methodology
This report is generated from a live ingest pipeline (tools/scout-ingest). Sources: FDA openFDA, ClinicalTrials.gov v2 API, PubMed E-utilities, SEC EDGAR, CMS Medicare Coverage Database, USPTO Patent Center, and manufacturer pipeline pages. Updated —. Every signal carries source URL and fetch timestamp; click any card to view origin.
Confidence framework. Source-backed > pattern-inferred > model-hypothesis > speculative. This report contains source-backed signals only. Pattern-inferred and model-hypothesis tiers are surfaced only inside member dashboards with explicit provenance flags.
Limitations. This is a public, ToS-compliant view. Closed-source manufacturer disclosures, ministry tenders, and private regulatory correspondence are out of scope for this surface. Members access an extended view with partner intelligence subject to NDA. Sovereign-tagged companies (KSA, GCC, MENA) reflect publicly observable regional headquarters; ministry-procurement detail is reserved for the partner intelligence surface.